Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Omeros reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings report.

Omeros exhibits exceptionally high volatility around earnings, with an average absolute Day +1 move of 21.15%—nearly six times the typical stock's post-earnings reaction. The historical pattern shows dramatic swings in both directions, with Day +1 moves ranging from a 65.87% surge (November 2024) to an 18.61% decline (May 2025).

The most recent earnings report (August 2026) exemplifies this volatility: the stock jumped 26.55% on Day +1 following the company's surprise profit and better-than-expected YARTEMLEA sales. This marked the second-largest post-earnings gain in the dataset and reflected investor enthusiasm about the commercial launch trajectory.

The Day 0 moves are more muted, averaging 3.56%, suggesting most of the price action occurs after investors digest the actual results and management commentary. However, the Day +1 range averages 23.91%, indicating that even when the directional move is moderate, intraday volatility remains extreme.

Investors should prepare for significant price movement following this report. Given the binary nature of the YARTEMLEA launch story and the lack of analyst consensus on adoption rates, the stock could easily move 15-25% in either direction depending on whether Q3 sales meet, exceed, or disappoint expectations.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.34% expected move for the upcoming earnings report, which sits well below the stock's historical average post-earnings move of 21.15%. This suggests options may be underpricing the potential volatility, creating potential opportunity for traders expecting an outsized reaction. The expected range of $14.98 to $20.00 reflects significant uncertainty, but history indicates the actual move could exceed these bounds—particularly given the high-stakes nature of the YARTEMLEA commercial update and the recent Medicare reimbursement catalyst.

Part 3: What Analysts Are Saying

Omeros currently holds a Buy rating from analysts, with a consensus price target of $36.67—implying 109.6% upside from the current price. The analyst community includes 2 Strong Buy ratings and 2 Hold ratings, with no sell recommendations.

Price targets range from a low of $22.00 to a high of $55.00, reflecting divergent views on YARTEMLEA's commercial potential. The wide spread suggests significant uncertainty about the drug's ultimate market penetration and peak sales trajectory.

Analyst sentiment has deteriorated slightly over the past month, with the Strong Buy count declining from 3 to 2, while the average recommendation slipped from 4.20 to 4.00. This modest pullback likely reflects profit-taking after the stock's strong run and growing questions about whether the Q2 sales surge can be sustained.

Despite the recent sentiment shift, the consensus remains decidedly bullish. The average price target of $36.67 suggests analysts believe the market is still significantly undervaluing Omeros' commercial opportunity, even after the stock's substantial appreciation. The key debate centers on execution: whether management can convert the promising early YARTEMLEA adoption into sustained, predictable revenue growth that justifies the elevated valuation expectations.

Part 4: Technical Picture

The Barchart Technical Opinion currently stands at 56% Buy, up from 40% Buy one week ago but down from 80% Buy one month ago. This recent strengthening from the weekly low suggests near-term momentum has improved heading into earnings, though the signal remains weaker than it was in mid-October.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum is balanced, with neither bulls nor bears in clear control ahead of the earnings event
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite recent consolidation
• Long-term (100% Buy): Strong buy signal reflects robust longer-term uptrend, consistent with the stock's substantial gains over the past year

Trend Characteristics: The signal shows Average strength with the Weakest direction, suggesting the uptrend remains intact but momentum has decelerated significantly from recent peaks—a cautionary setup heading into a high-volatility earnings event.

From a moving average perspective, the stock is trading below its 5-day ($17.70), 10-day ($17.67), and 50-day ($18.27) averages, indicating short-term weakness. However, it remains above its 20-day ($17.42), 100-day ($15.80), and 200-day ($13.77) averages, confirming the longer-term uptrend remains intact.

The technical setup heading into earnings is mixed: while the longer-term trend remains firmly bullish, the stock has pulled back from recent highs and is trading below key short-term moving averages. The 50-day average at $18.27 represents immediate resistance, while the 20-day at $17.42 provides nearby support. The deteriorating short-term momentum combined with the stock's history of extreme post-earnings volatility creates a high-risk, high-reward setup. Traders should be prepared for a significant move in either direction, with the technical picture suggesting the stock is coiled and ready to break out of its recent consolidation pattern once the YARTEMLEA sales numbers are revealed.